Filippo de Marinis

List of Publications by Year
in descending order

120	8,839	136740	45213
papers	citations	32 h-index	90 g-index

121	121	121	10105
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety Analysis of Salvage Surgery for Advanced Stages or Metastatic Lung Cancers. Thoracic and Cardiovascular Surgeon, 2022, 70, 273-276.	0.4	8
2	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	3.2	14
3	Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. Current Oncology, 2022, 29, 255-266.	0.9	27
4	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. Journal of Thoracic Oncology, 2021, 16, 764-773.	0.5	128
5	Surgery for small cell lung cancer: When and how. Lung Cancer, 2021, 152, 71-77.	0.9	18
6	Afatinib in EGFR TKI-naÃ¯ve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer, 2021, 152, 127-134.	0.9	17
7	CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer. Lancet Oncology, The, 2021, 22, 157-159.	5.1	10
8	What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences. Frontiers in Pharmacology, 2021, 12, 602112.	1.6	6
9	Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. Cancers, 2021, 13, 2172.	1.7	25
10	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer, 2021, 154, 151-160.	0.9	25
11	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	3.2	44
12	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1â€“Selected NSCLC. Journal of Thoracic Oncology, 2021, 16, 1872-1882.	0.5	85
13	Afatinib in EGFR TKI-NaÃ¯ve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology, 2021, 11, 709877.	1.3	6
14	Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review. Translational Lung Cancer Research, 2021, 10, 3401-3408.	1.3	2
15	A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers in Oncology, 2021, 11, 676732.	1.3	14
16	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. Journal of Thoracic Oncology, 2021, 16, 2040-2050.	0.5	26
17	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	1.5	4
18	Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study. Journal of Clinical Medicine, 2021, 10, 3465.	1.0	3

#	Article	IF	Citations
19	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1369-1378.	0.5	31
20	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Current Oncology, 2021, 28, 3384-3392.	0.9	4
21	Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study. Jornal Brasileiro De Pneumologia, 2021, 47, e20200584.	0.4	5
22	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncology, 2021, 17, 4649-4656.	1.1	0
23	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2021, 22, 1438-1447.	5.1	45
24	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. Anticancer Research, 2020, 40, 427-433.	0.5	16
25	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers, 2020, 12, 2948.	1.7	14
26	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 2020, 383, 2018-2029.	13.9	592
27	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1810-1821.	1.3	7
28	Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey. Frontiers in Oncology, 2020, 10, 584612.	1.3	19
29	Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Annals of Translational Medicine, 2020, 8, 1111-1111.	0.7	2
30	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. Cancer Treatment Reviews, 2020, 89, 102085.	3.4	41
31	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open, 2020, 5, e000820.	2.0	96
32	O81â€…IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1â€“selected NSCLC. , 2020, , .		6
33	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Nonâ€“Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	1.4	4
34	Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model. Frontiers in Oncology, 2020, 10, 665.	1.3	27
35	Overcoming resistance to osimertinib in nonâ€“small cell lung cancer: Hopes, doubts, and inâ€between. Cancer, 2020, 126, 2594-2596.	2.0	6
36	Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT). Cancers, 2020, 12, 1627.	1.7	10

#	Article	IF	Citations
37	Lung cancer surgery in oligometastatic patients: outcome and survival. European Journal of Cardio-thoracic Surgery, 2020, 57, 1173-1180.	0.6	28
38	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer, 2020, 142, 70-79.	0.9	17
39	Reply. Clinical Lung Cancer, 2020, 21, e415-e416.	1.1	0
40	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	1.8	62
41	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. Anticancer Research, 2019, 39, 4265-4271.	0.5	33
42	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. Future Oncology, 2019, 15, 3003-3014.	1.1	42
43	Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice. Expert Review of Respiratory Medicine, 2019, 13, 217-228.	1.0	9
44	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€“Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	3.2	139
45	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. Cancers, 2019, 11, 1431.	1.7	7
46	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.3	24
47	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. Journal of Clinical Medicine, 2019, 8, 112.	1.0	7
48	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of AlectinibÂinÂUntreated ALK-Positive Advanced Nonâ€“Small CellÂLung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology, 2019, 14, 1233-1243.	0.5	324
49	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.3	14
50	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. Oncologist, 2019, 24, e1165-e1171.	1.9	35
51	Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. Translational Lung Cancer Research, 2019, 8, S334-S338.	1.3	1
52	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies . Lung Cancer: Targets and Therapy, 2019, Volume 10, 125-130.	1.3	6
53	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer, 2019, 128, 105-112.	0.9	126
54	Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?. Clinical Lung Cancer, 2019, 20, 97-106.e1.	1.1	16

#	Article	IF	Citations
55	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer, 2019, 129, 35-40.	0.9	122
56	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194.	1.1	40
57	Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding. Annals of Translational Medicine, 2019, 7, S80-S80.	0.7	6
58	Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets. Chinese Clinical Oncology, 2019, 8, S1-S1.	0.4	7
59	Evaluation of target coverage and margins adequacy during CyberKnife Lung Optimized Treatment. Medical Physics, 2018, 45, 1360-1368.	1.6	16
60	Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Current Medical Research and Opinion, 2018, 34, 865-871.	0.9	5
61	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. Stem Cells, 2018, 36, 633-640.	1.4	32
62	Second-Line Treatment Options in Nonâ€“Small-CellÂLung Cancer: Report From anÂInternational Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	1.1	7
63	Acquired Resistance to Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasoundâ€“Guided Transbronchial Needle Aspiration Samples. Archives of Pathology and Laboratory Medicine, 2018, 142, 465-473.	1.2	4
64	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. Journal of Clinical Pathology, 2018, 71, 767-773.	1.0	14
65	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. British Journal of Cancer, 2018, 118, 38-42.	2.9	23
66	Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. Translational Lung Cancer Research, 2018, 7, S100-S102.	1.3	7
67	A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. Journal of Thoracic Disease, 2018, 10, 3928-3939.	0.6	15
68	Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterfly. Pulmonology, 2018, 24, 321-322.	1.0	0
69	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncology, The, 2018, 19, 1468-1479.	5.1	370
70	Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a â€˜no-fly zoneâ€™?. Acta OncolÃ³gica, 2018, 57, 1532-1539.	0.8	7
71	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. Current Clinical Pharmacology, 2018, 13, 76-84.	0.2	9
72	The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. Immunotherapy, 2018, 10, 1041-1045.	1.0	5

#	Article	IF	Citations
73	Italian Nivolumab Expanded Access Program inÂNonsquamous Nonâ€“Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155.	0.5	77
74	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1156-1170.	0.5	195
75	30 Immunotherapy in advanced NSCLCâ€”from the â€˜tsunamiâ€™ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2018, 3, e000298.	2.0	10
76	Use of nivolumab in elderly patients with advanced squamous nonâ€“small-cell lung cancer: results from the Italian cohort of an expanded access programme. European Journal of Cancer, 2018, 100, 126-134.	1.3	83
77	Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS ONE, 2018, 13, e0202865.	1.1	50
78	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9043-9043.	0.8	45
79	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacological Research, 2017, 117, 406-415.	3.1	55
80	Salvage Surgery After Definitive Chemoradiotherapy for Nonâ€“small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 233-241.	0.4	51
81	Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2017, 52, 975-981.	0.6	9
82	Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. Clinical Lung Cancer, 2017, 18, 489-496.	1.1	14
83	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, The, 2017, 389, 255-265.	6.3	3,872
84	Lung Tissue Injury as an Atypical Response to Nivolumab in Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1349-1350.	2.5	4
85	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. European Journal of Cancer, 2017, 87, 131-139.	1.3	35
86	ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm. JCO Precision Oncology, 2017, 1, 1-9.	1.5	9
87	The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. Journal of Thoracic Disease, 2017, 9, S1501-S1510.	0.6	18
88	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Translational Lung Cancer Research, 2017, 6, 373-386.	1.3	45
89	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036.	0.8	10
90	Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?. Journal of Thoracic Disease, 2016, 8, E217-E220.	0.6	9

#	Article	IF	Citations
91	Proposals for revisions of the classification of lung cancers with multiple pulmonary sites: the radiologistâ€™s, thoracic surgeonâ€™s and oncologistâ€™s point of view. Journal of Thoracic Disease, 2016, 8, E805-E808.	0.6	1
92	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. OncoTargets and Therapy, 2016, Volume 9, 6361-6376.	1.0	21
93	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37.	0.9	31
94	First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?. Expert Review of Anticancer Therapy, 2016, 16, 799-801.	1.1	2
95	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Nonâ€“Small Cell Lung Cancer: Realities and Hopes. Journal of Thoracic Oncology, 2016, 11, 1153-1169.	0.5	9
96	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 461-465.	1.1	37
97	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opinion on Biological Therapy, 2016, 16, 1479-1489.	1.4	10
98	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert Review of Clinical Pharmacology, 2016, 9, 1283-1288.	1.3	2
99	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Nonâ€“Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of Clinical Oncology, 2016, 34, 2866-2873.	0.8	316
100	Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. Clinical Lung Cancer, 2016, 17, e179-e183.	1.1	6
101	Outcome of Patients With pN2 â€œPotentially Resectableâ€•Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 593-602.	0.4	14
102	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. Journal of Thoracic Oncology, 2016, 11, 801-807.	0.5	21
103	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. European Radiology, 2016, 26, 32-42.	2.3	210
104	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.. Journal of Clinical Oncology, 2016, 34, 3067-3067.	0.8	4
105	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer. Oncotarget, 2016, 7, 37160-37176.	0.8	8
106	Molecular biomarkers in early-stage lung cancer.. Journal of Clinical Oncology, 2016, 34, e23082-e23082.	0.8	0
107	Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). OncoTargets and Therapy, 2015, 8, 1997.	1.0	14
108	Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. Future Oncology, 2015, 11, 421-429.	1.1	9

#	Article	IF	Citations
109	Molecular Testing for Targeted Therapy in Advanced Nonâ€“Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. American Journal of Clinical Pathology, 2015, 144, 629-634.	0.4	65
110	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	0.8	6
111	Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. OncoTargets and Therapy, 2014, 7, 697.	1.0	7
112	Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 418-425.	1.1	31
113	Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Therapeutic Advances in Medical Oncology, 2014, 6, 101-114.	1.4	178
114	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 713-721.	5.1	157
115	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2014, 90, 135-145.	2.0	12
116	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2014, 15, 411-417.e4.	1.1	32
117	Afatinib-Related Nonhematologic Adverse Events: Is Common Evaluation Enough for Now?. Journal of Clinical Oncology, 2014, 32, 864-865.	0.8	4
118	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2014, 15, 173-181.	1.1	56
119	Afatinib in NSCLC harbouring EGFR mutations. Lancet Oncology, The, 2014, 15, e148-e149.	5.1	7
120	Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review). International Journal of Oncology, 2014, 45, 509-515.	1.4	12